Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Co.'s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. Co.'s primary product candidate, GB0139, is an inhaled inhibitor of galectin-3. Co. is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. We show 14 historical shares outstanding datapoints in our GLTO shares outstanding history coverage, used to compute GLTO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GLTO market cap history over the course of time is important for investors
interested in comparing GLTO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GLTO versus a peer is one thing; comparing
GLTO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GLTO can fluctuate over the course of history.
With this page we aim to empower investors researching GLTO by allowing them to research the GLTO market cap history. |
Free GLTO Email Alerts:
Video: The Importance of Market Cap
